Securities investigation adds to TruBridge's risk profile

What happened

TruBridge faces a securities class action investigation by Rosen Law Firm over allegations it issued materially misleading business information to investors. This litigation risk compounds existing concerns from the DeepValue report, which highlights high leverage (Net Debt/EBITDA 4.65x), persistent internal control weaknesses, and a full valuation (EV/EBITDA ~13x). Despite improving execution with 94% recurring revenue and positive free cash flow, bookings declined year-over-year in Q3 2025, signaling potential demand softness. The investigation could distract management and erode investor confidence, particularly given the company's fragile balance sheet and credit agreement restrictions. The stock, trading at $21 with a negative P/E, offers limited downside protection and a wide gap to the DCF intrinsic value of $4.47.

Implication

The Rosen investigation introduces legal overhang that may suppress the stock and increase volatility. Combined with high leverage, internal control remediation, and a full valuation, the risk/reward is unfavorable. While secular RCM tailwinds exist, the upside is capped until the company de-levers to below 4.0x Net Debt/EBITDA, shores up controls, and re-accelerates bookings. The DCF anchor of $4.47 suggests significant downside if fundamentals deteriorate further. Patience is warranted; wait for a better entry point or clarity on litigation.

Thesis delta

The previous 'WAIT' judgment assumed litigation risk was not imminent; the investigation materially raises the probability of adverse outcomes. Thesis shifts from 'wait for deleveraging and fundamentals' to 'wait for resolution of securities claims alongside operational improvements.' Any near-term positive catalyst is outweighed by legal and balance sheet overhang.